Ru Feng

2.1k total citations
93 papers, 998 citations indexed

About

Ru Feng is a scholar working on Pathology and Forensic Medicine, Hematology and Oncology. According to data from OpenAlex, Ru Feng has authored 93 papers receiving a total of 998 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pathology and Forensic Medicine, 33 papers in Hematology and 24 papers in Oncology. Recurrent topics in Ru Feng's work include Lymphoma Diagnosis and Treatment (34 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Viral-associated cancers and disorders (15 papers). Ru Feng is often cited by papers focused on Lymphoma Diagnosis and Treatment (34 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Viral-associated cancers and disorders (15 papers). Ru Feng collaborates with scholars based in China, United States and Australia. Ru Feng's co-authors include Yongqiang Wei, Xiaolei Wei, Yao He, Zhi Chen, Fen Huang, Xiang Chen, Bingsheng Li, Bo Zhang, Guoyu Dai and Weiping Xia and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Ru Feng

81 papers receiving 984 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ru Feng China	17	373	319	273	231	198	93	998
Styliani Kokoris Greece	19	271 0.7×	214 0.7×	210 0.8×	213 0.9×	123 0.6×	55	899
Hung Chang Taiwan	18	254 0.7×	252 0.8×	142 0.5×	235 1.0×	144 0.7×	98	1.0k
Burhan Ferhanoğlu Türkiye	14	505 1.4×	453 1.4×	262 1.0×	212 0.9×	94 0.5×	78	1.1k
Neta Goldschmidt Israel	23	514 1.4×	331 1.0×	425 1.6×	355 1.5×	154 0.8×	97	1.4k
Rika Sakai Japan	24	581 1.6×	526 1.6×	370 1.4×	465 2.0×	147 0.7×	107	1.5k
Nataša Čolović Serbia	17	186 0.5×	161 0.5×	202 0.7×	344 1.5×	108 0.5×	119	908
Amy J. Wagner United States	20	384 1.0×	267 0.8×	570 2.1×	145 0.6×	394 2.0×	76	1.8k
Cédric Garcia France	16	212 0.6×	150 0.5×	303 1.1×	374 1.6×	124 0.6×	39	996
Driss Chaoui France	16	161 0.4×	478 1.5×	196 0.7×	324 1.4×	116 0.6×	29	1.1k
Itai Levi Israel	16	212 0.6×	206 0.6×	245 0.9×	400 1.7×	117 0.6×	60	844

Countries citing papers authored by Ru Feng

Since Specialization

Citations

This map shows the geographic impact of Ru Feng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ru Feng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ru Feng more than expected).

Fields of papers citing papers by Ru Feng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ru Feng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ru Feng. The network helps show where Ru Feng may publish in the future.

Co-authorship network of co-authors of Ru Feng

This figure shows the co-authorship network connecting the top 25 collaborators of Ru Feng. A scholar is included among the top collaborators of Ru Feng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ru Feng. Ru Feng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lasica, Masa, Sikander Ailawadhi, Chengcheng Fu, et al.. (2024). Updated efficacy and safety results of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM).. Journal of Clinical Oncology. 42(16_suppl). 7078–7078. 1 indexed citations

Xiong, Dan, et al.. (2024). Prediction significance of autophagy-related genes in survival probability and drug resistance in diffuse large B-cell lymphoma. Aging. 16(2). 1049–1076. 6 indexed citations

Wei, Xiaolei, Yue Zhu, Xianfeng Zha, et al.. (2024). Single‐Cell Multiomics Reveals TCR Clonotype‐Specific Phenotype and Stemness Heterogeneity of T‐ALL Cells. Cell Proliferation. 58(4). e13786–e13786. 1 indexed citations

Feng, Ru, et al.. (2023). Validation and modification of simplified Geriatric Assessment and Elderly Prognostic Index: Effective tools for older patients with diffuse large B‐cell lymphoma. Cancer Medicine. 13(1). e6856–e6856. 3 indexed citations

Zhang, Yunxia, et al.. (2023). Curcumin Enhances Ibrutinib Induced Killing Effect Against TP53-Mutated Chronic Lymphocytic Leukemia Cells in Vitro. Blood. 142(Supplement 1). 5792–5792. 1 indexed citations

Song, Yuqin, Shuhua Yi, Haiyan Yang, et al.. (2023). Pirtobrutinib, a Non-Covalent (reversible) BTK Inhibitor, in Mantle Cell Lymphoma Patients Previously Treated with a Covalent BTK Inhibitor: Results from a China Phase 2 Study. Blood. 142(Supplement 1). 3636–3636. 1 indexed citations

Song, Yuqin, Keshu Zhou, Shenmiao Yang, et al.. (2023). Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma. Investigational New Drugs. 41(4). 606–616. 1 indexed citations

Zhang, Bo, Xiang Chen, Ru Feng, et al.. (2021). Liproxstatin-1 attenuates unilateral ureteral obstruction-induced renal fibrosis by inhibiting renal tubular epithelial cells ferroptosis. Cell Death and Disease. 12(9). 843–843. 158 indexed citations

Qiao, Jing, Yu Gan, Bo Zhang, et al.. (2021). Combination therapy with curcumin plus tamsulosin and finasteride in the treatment of men with benign prostatic hyperplasia: a single center, randomized control study. Translational Andrology and Urology. 10(8). 3432–3439. 9 indexed citations

10.

Song, Yuqin, Keshu Zhou, Dehui Zou, et al.. (2020). Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase. Clinical Cancer Research. 26(16). 4216–4224. 111 indexed citations

11.

Gao, Yan, Huiqiang Huang, Xiaoxiao Wang, et al.. (2020). Anti-PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single-Arm, Phase Ib/II Trial (SCENT). Blood. 136(Supplement 1). 39–40. 20 indexed citations

12.

Xue, Jing, Ru Feng, Hai‐Xia Fu, et al.. (2018). Combined prednisone and levothyroxine improve treatment of severe thrombocytopenia in hepatitis B with compensatory cirrhosis accompanied by subclinical and overt hypothyroidism. Science China Life Sciences. 61(8). 924–933. 1 indexed citations

13.

Huang, Weimin, Xiaolei Wei, Yongqiang Wei, & Ru Feng. (2018). Biology of Tumor Associated Macrophages in Diffuse Large B Cell Lymphoma. DNA and Cell Biology. 37(12). 947–952. 2 indexed citations

14.

Feng, Feier, Ru Feng, Min Wang, et al.. (2017). Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial. The Lancet Haematology. 4(10). e487–e496. 39 indexed citations

15.

Wei, Yongqiang, Fen Huang, Xiaolei Wei, et al.. (2016). Low prognostic nutritional index predicts poor outcome in diffuse large B-cell lymphoma treated with R-CHOP. International Journal of Hematology. 104(4). 485–490. 32 indexed citations

16.

Zhang, Xiaohui, Yun He, Ru Feng, et al.. (2015). Helicobacter pyloriinfection influences the severity of thrombocytopenia and its treatment response in chronic hepatitis B patients with compensatory cirrhosis: A multicenter, observational study. Platelets. 27(3). 223–229. 6 indexed citations

17.

Feng, Ru. (2015). The international staging system predicts outcome in diffuse large B-cell lymphoma treated with R-chop. Experimental Hematology. 43(9). S62–S62.

18.

Zhang, Xiaohui, Xiaolu Zhu, Ting Niu, et al.. (2015). Combination of FVIII and low-dose rFVIIa improves haemostasis in acquired haemophilia A patients: a collaborative controlled study. Thrombosis Research. 135(5). 835–840. 3 indexed citations

19.

Zhang, Xiao Hui, Ru Feng, Lan Xu, et al.. (2014). Immunosuppressive treatment combined with nucleoside analog is superior to nucleoside analog only in the treatment of severe thrombocytopenia in patients with cirrhosis associated with hepatitis B in China: A multicenter, observational study. Platelets. 26(7). 672–679. 7 indexed citations

20.

Feng, Ru. (2013). Immunophenotype and Prognosis in 510 Patients with Acute Myeloid Leukemia:A Single-Center Study. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact